A Recent Review of the Management of Postmenopausal Symptoms in Breast Cancer Survivors

키워드

참고문헌 (42)

1. Micha JP, "Hormone therapy and risk of breast cancer: where are we now?", J Menopausal Med, 28, pp.47~51 (2022)
2. Pandya KJ, "Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer", Breast Cancer Res Treat, 83, pp.87~89 (2004)
3. Fisher WI, "Risk factors, pathophysiology, and treatment of hot flashes in cancer", CA Cancer J Clin, 63, pp.167~192 (2013)
4. Nonhormonal management of menopause-associated vasomotor symptoms, "2015 position statement of The North American Menopause Society", Menopause, 22, pp.1155~1172 (2015)
5. Desmarais JE, "Interactions between tamoxifen and antidepressants via cytochrome P450 2D6", J Clin Psychiatry, 70, pp.1688~1697 (2009)
6. Carpenter JS, "Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer", Oncologist, 12, pp.124~135 (2007)
7. Shan D, "Efficacy and safety of gabapentin and pregabalin in patients with vasomotor symptoms : a systematic review and meta-analysis", Am J Obstet Gynecol, 222, pp.564~579 (2020)
8. Pandya KJ, "Gabapentin for hot flashes in 420 women with breast cancer : a randomised double-blind placebo-controlled trial", Lancet, 366, pp.818~824 (2005)
9. The 2023 Nonhormone Therapy Position Statement of The North American Menopause SocietyAdvisory Panel, "The 2023nonhormone therapy position statement of The North American Menopause Society", Menopause, 30, pp.573~590 (2023)
10. Pezzella G, "Treatment of depression in patients with breast cancer : a comparison between paroxetine and amitriptyline", Breast Cancer Res Treat, 70, pp.1~10 (2001)
11. Morrow GR, "Differential effects of paroxetine on fatigue and depression : a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program", J Clin Oncol, 21, pp.4635~4641 (2003)
12. Ma Y, "Efficacy of cognitive behavioral therapy for insomnia in breast cancer : a metaanalysis", Sleep Med Rev, 55, pp.101376~ (2021)
13. Aydin M, "The effect of exercise on life quality and depression levels of breast cancer patients", Asian Pac J Cancer Prev, 22, pp.725~732 (2021)
14. Suhyun Shim, "Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements", 대한폐경학회지, 27(1), pp.1~7 (2021), 대한폐경학회[DOI]
15. Crandall CJ, "Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Womens Health Initiative Observational Study", Menopause, 25, pp.11~20 (2018)
16. Dew JE, "A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer", Climacteric, 6, pp.45~52 (2003)
17. Le Ray I, "Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients : a nested case-control study", Breast Cancer Res Treat, 135, pp.603~609 (2012)
18. "ACOG Committee Opinion No. 659: The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer", Obstet Gynecol, 127, pp.e93~6 (2016)
19. Goetsch MF, "A practical solution for dyspareunia in breast cancer survivors : a randomized controlled trial", J Clin Oncol, 33, pp.3394~3400 (2015)
20. Beckwée D, "Prevalence of aromatase inhibitor-induced arthralgia in breast cancer : a systematic review and meta-analysis", Support Care Cancer, 25, pp.1673~1686 (2017)
21. Grigorian N, "Aromatase inhibitor-associated musculoskeletal pain : an overview of pathophysiology and treatment modalities", SAGE Open Med, 10, pp.20503121221078722~ (2022)
22. Khan QJ, "Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer", Breast Cancer Res Treat, 119, pp.111~118 (2010)
23. Greenlee H, "Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer", Support Care Cancer, 21, pp.1077~1087 (2013)
24. Hershman DL, "Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer : a randomized clinical trial", JAMA, 320, pp.167~176 (2018)
25. Tzeng HE, "Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia : a nationwide population-based cohort study", BMC Musculoskelet Disord, 16, pp.123~ (2015)
26. Kristensen B, "Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen", Breast Cancer Res Treat, 39, pp.321~326 (1996)
27. Cooke AL, "Tamoxifen use and osteoporotic fracture risk : a population-based analysis", J Clin Oncol, 26, pp.5227~5232 (2008)
28. Waqas K, "Updated guidance on the management of cancer treatmentinduced bone loss(CTIBL)in pre-and postmenopausal women with early-stage breast cancer", J Bone Oncol, 28, pp.100355~ (2021)
29. Gnant M, "Role of bisphosphonates in postmenopausal women with breast cancer", Cancer Treat Rev, 40, pp.476~484 (2014)
30. Van Poznak C, "Prevention of aromatase inhibitor-induced bone loss using risedronate : the SABRE trial", J Clin Oncol, 28, pp.967~975 (2010)
31. Bundred NJ, "Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST Study results", Cancer, 112, pp.1001~1010 (2008)
32. Trémollieres FA, "Osteoporosis management in patients with breast cancer : EMAS position statement", Maturitas, 95, pp.65~71 (2017)
33. Datta M, "Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy", Crit Rev Oncol Hematol, 88, pp.613~624 (2013)
34. Dieli-Conwright CM, "Aerobic and resistance exercise improves physical fitness, bone health, and quality of life in overweight and obese breast cancer survivors : a randomized controlled trial", Breast Cancer Res, 20, pp.124~ (2018)
35. Greenlee H, "Risk of cardiovascular disease in women with and without breast cancer : the pathways heart study", J Clin Oncol, 40, pp.1647~1658 (2022)
36. Yu Q, "Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen : a systematic review and meta-analysis", J Clin Pharm Ther, 47, pp.575~587 (2022)
37. Ahles TA, "Cancer-and cancer treatmentassociated cognitive change : an update on the state of the science", J Clin Oncol, 30, pp.3675~3686 (2012)
38. Inagaki M, "Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy", Cancer, 109, pp.146~156 (2007)
39. Vodermaier A., "Breast cancer treatment and cognitive function:the current state of evidence, underlying mechanisms and potential treatments", Womens Health(Lond), 5, pp.503~516 (2009)
40. Kohli S, "The effect of modafinil on cognitive function in breast cancer survivors", Cancer, 115, pp.2605~2616 (2009)
41. Haskell SG, "The effect of raloxifene on cognitive function in postmenopausal women : a randomized clinical trial", Conn Med, 68, pp.355~358 (2004)
42. Ren X, "Effects of physical exercise on cognitive function of breast cancer survivors receiving chemotherapy : a systematic review of randomized controlled trials", Breast, 63, pp.113~122 (2022)

관련 논문AI추천